AXS-12 Phase 3 Trial Enrolls First Individual

Article

Axsome Therapeutics continues to explore its narcolepsy drug after the FDA granted it orphan drug designation.

Axsome Therapeutics, Inc, has enrolled its first individual in the Study Evaluating a Mechanistic Approach to Treating Narcolepsy (SYMPHONY) of its new oral norepinephrine reuptake inhibitor, AXS-12.

“The advancement of AXS-12 into phase 3 testing for narcolepsy demonstrates Axsome’s commitment to developing important new medicines for patients living with serious CNS conditions,” Herriot Tabuteau, MD, chief executive officer of Axsome, said in a statement.

“Narcolepsy impairs almost every aspect of a patient’s life, including cognitive, psychological, social, and emotional functioning. If successfully developed, AXS-12 may address multiple symptoms of this debilitating condition,” Tabuteau said.

SYMPHONY is a double-blind, placebo-controlled, randomized trial with individuals who have narcolepsy.

The FDA has granted AXS-12 orphan drug designation to treat narcolepsy.

Top-line results from the study are expected in the first half of 2023.

Reference

Axsome Therapeutics initiates SYMPHONY Phase 3 Trails of AXS-12 in Narcolepsy. Yahoo! Finance. News release. September 16, 2021. Accessed September 24, 2021. https://finance.yahoo.com/news/axsome-therapeutics-initiates-symphony-phase-110000378.html

Related Videos
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
cropped view of man performing chest compression on dummy during cpr training class - Image credit: LIGHTFIELD STUDIOS | stock.adobe.com
Medicine law concept. Judges gavel with pills | Image Credit: Iren Moroz - stock.adobe.com
Image credit: New Africa | stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
Image credit: alicja neumiler | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Image Credit: Pixel-Shot | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.